Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism-Reference-Cited by-同舟云学术

Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism

Published:2015-10-16 Issue:35 Volume:6 Page:37200-37215
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Sureban Sripathi M.¹²³,Madhoun Mohammad F.¹²,May Randal¹²,Qu Dongfeng¹²³,Ali Naushad¹²³,Fazili Javid¹²,Weygant Nathaniel¹,Chandrakesan Parthasarathy¹³,Ding Kai⁴,Lightfoot Stanley A.⁵,Houchen Courtney W.¹²³⁶

Affiliation:

1. Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

2. Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104, USA

3. The Peggy and Charles Stephenson Cancer Center, Oklahoma City, OK 73104, USA

4. Department of Biostatistics & Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

5. Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

6. COARE Biotechnology Inc., Oklahoma City, OK 73104, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Histone Acetylation-Related Gene Signature for Prediction of Prognosis and Immunotherapy Efficacy in Stomach Adenocarcinoma and Verification in vitro;2024-08-09

2. From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases;International Journal of Molecular Sciences;2024-06-12

3. Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma;Molecular Cell;2024-02

4. DCLK1 is Overexpressed and Associated with Immune Cell Infiltration in Hepatocellular Carcinoma;Biochemical Genetics;2024-01-31

5. DCLK1 and its oncogenic functions: A promising therapeutic target for cancers;Life Sciences;2024-01